

IN THE CLAIMS:

Please amend the Claims as follows:

1. (Twice Amended) An immunogenic composition comprising an adjuvant and an antigen; wherein said adjuvant and said antigen are joined together; wherein said adjuvant is selected from the group consisting of an antibody that binds cell surface receptor CD40, a part of said antibody that is effective at binding CD40, and a CD40 ligand; and  
wherein when said adjuvant [is adapted to stimulate] binds to CD40 of a B-lymphocyte cell [surface receptor, CD40] said adjuvant helps in activating said B-lymphocyte cell.
4. (Amended) A vaccine according to Claim 2 wherein said adjuvant is a CD40 ligand [or part thereof].

REMARKS

Reconsideration of this Application is respectfully requested. Claims 1 and 4 have been amended to more particularly point out and distinctly claim the subject matter of the invention. Applicant reserves the right to bring back the subject matter of the canceled portion of the claims in a later filing. Support for the amendments to the claims can be found throughout the Specification as filed, including in the original claims. More particularly, further support for the amendment to Claim 1 can be found in the Specification as originally filed on line 24 of Page 2 through line 3 of Page 3; Page 3 lines 15-21; Page 5, lines 1-3, and lines 14-22; and Page 7, lines 8 and 9. If the proposed Amendment is entered, newly amended Claims 1 and 4 and Claims 2, 3, 5-10, 12, 13, and 15-23 will remain for consideration. No new matter has been entered.

Rejections under 35 U.S.C. § 112, first and second paragraph:

The Examiner has maintained the rejection to Claims 1-4, 8-10, 12, 13, and 15-23 under 35 U.S.C. § 112, first and second paragraphs asserting that the phrases, “adjuvant which is adapted to stimulate a B lymphocyte cell surface receptor, CD40” and “parts thereof” as it refers